{
    "clinical_study": {
        "@rank": "8042", 
        "arm_group": [
            {
                "arm_group_label": "Dosing Period 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dosing Period 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, open-label, cross-over study will evaluate the effect of fluvoxamine on\n      the pharmacokinetics of RO4917523 in healthy volunteers. Healthy volunteers will receive a\n      single dose of RO4917523 alone and in combination with multiple doses of fluvoxamine in a\n      cross-over design. The anticipated time on study treatment is 40 days."
        }, 
        "brief_title": "A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers, 18-65 years of age inclusive\n\n          -  Non-smokers\n\n          -  Body mass index (BMI) between 18 and 30 mg/m2 inclusive\n\n          -  Women who are not menopausal or surgically sterile agree to use two adequate methods\n             of contraception\n\n        Exclusion Criteria:\n\n          -  Evidence of any active or chronic disease\n\n          -  History of any significant disease (e.g., cardiovascular, hepatic, renal) or cancer\n             History or presence of clinically significant psychiatric condition\n\n          -  Any condition or disease that would render the volunteer unsuitable for the study,\n             place the volunteer at undue risk or interfere with the ability of the volunteer to\n             complete the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665404", 
            "org_study_id": "BP28250", 
            "secondary_id": "2012-000772-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dosing Period 1", 
                    "Dosing Period 2"
                ], 
                "description": "Single dose of RO4917523", 
                "intervention_name": "RO4917523", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dosing Period 2", 
                "description": "Multiple doses of fluvoxamine", 
                "intervention_name": "Fluvoxamine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluvoxamine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35042"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Fluvoxamine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: ANSM - French Health Products Safety Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics: Area under the concentration time curve", 
            "safety_issue": "No", 
            "time_frame": "Period 1: Pre-dose and up to Day 14, Period 2: pre-dose and up to Day 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "9 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}